Autoimmune Pancreatitis

Autoimmune Pancreatitis — scientific infographic poster
  1. Overview
  2. Type 1 vs Type 2 AIP — Two Distinct Diseases
  3. IgG4-Related Disease — The Systemic Connection
  4. Clinical Presentation — Mimicking Pancreatic Cancer
  5. Imaging Features — Sausage Pancreas and Duct Changes
  6. Diagnosis — HISORt Criteria
  7. Treatment — Steroids and Relapse Prevention
  8. Complications and Long-Term Course
  9. Key Research Papers
  10. Connections
  11. Featured Videos

Overview

Autoimmune pancreatitis (AIP) is an immune-mediated fibroinflammatory disease of the pancreas that behaves nothing like the gallstone or alcohol-driven pancreatitis most people know. Rather than causing the sudden, severe abdominal pain that characterizes typical acute pancreatitis, AIP typically causes painless obstructive jaundice — and it does so in a way that so closely resembles pancreatic cancer that it has led to unnecessary major surgery in patients who would have responded completely to a short course of steroids.

Specialists describe the central clinical lesson of AIP this way: before an operation on what appears to be a pancreatic head mass with biliary obstruction, autoimmune pancreatitis belongs on the list of possibilities. A trial of corticosteroids — with rapid, dramatic improvement as the expected response — can spare patients a pancreaticoduodenectomy (Whipple procedure) for a benign, steroid-responsive disease.

AIP is not a single disease. Two clinically and pathologically distinct subtypes exist, united by their response to immunosuppression but differing in their underlying mechanism, affected patient population, associated conditions, relapse behavior, and histological fingerprint. The distinction shapes both how AIP is diagnosed and how intensively it is managed long-term.

AIP is rare, though recorded numbers are rising. Japan, where the condition was first systematically described, estimated 16,750 people with AIP in its fifth nationwide survey (2021 data): 13.3 per 100,000 people, a 25% increase since 2016, with about 3.4 new cases per 100,000 people a year. In that survey patients were mostly men (3.3 men to every woman), the average age at diagnosis was 66 years, other organs were involved in 68% (most often the bile ducts), and cancers caused 40% of deaths, although long-term survival overall was favourable. Rates are thought to be somewhat lower in Western countries. Despite its rarity, AIP has garnered enormous clinical interest because of its cancer-mimicking presentation and its complete reversibility with treatment.

Back to Table of Contents

Type 1 vs Type 2 AIP — Two Distinct Diseases

The recognition that "autoimmune pancreatitis" encompasses two biologically separate conditions was one of the most important refinements in gastroenterology over the past two decades. The 2011 International Consensus Diagnostic Criteria (ICDC) formalized this distinction.

Type 1 AIP — IgG4-Related Pancreatitis: Type 1 is the more common form, accounting for approximately 60–80% of AIP cases in Western countries and an even higher proportion in Japan and Korea. It is the pancreatic manifestation of IgG4-related disease (IgG4-RD), a systemic fibro-inflammatory condition that can affect virtually any organ. Pathological hallmarks are dense lymphoplasmacytic infiltration with abundant IgG4-positive plasma cells (>10 per high-power field), storiform (swirling, cartwheel-pattern) fibrosis, obliterative phlebitis (inflammatory destruction of veins), and granulocyte epithelial lesion (GEL) absence. These four histological features — lymphoplasmacytic infiltrate, storiform fibrosis, obliterative phlebitis, IgG4+ plasma cells — together define LPSP (lymphoplasmacytic sclerosing pancreatitis), the histological name for Type 1 AIP.

Type 1 AIP primarily affects older men — median age at diagnosis 60–70 years, with a male-to-female ratio of approximately 3–4:1. Serum IgG4 is elevated (above the upper limit of normal) in approximately 60–80% of Type 1 patients; levels greater than twice the upper limit of normal are more specific but miss many cases (see the test figures under IgG4-Related Disease below). In an international study of 1,064 patients, 31% of people with Type 1 relapsed, and in Japan's 2021 survey relapses kept adding up over the years (see Relapse under Treatment), and some require long-term maintenance immunosuppression or rituximab for relapse-prone disease.

Type 2 AIP — Idiopathic Duct-Centric Pancreatitis (IDCP): Type 2 is less common and distinct in every important way from Type 1. Its defining histological feature is the granulocytic epithelial lesion (GEL) — neutrophilic infiltration and destruction of pancreatic duct epithelium. Serum IgG4 levels are normal. The systemic IgG4-RD context is absent. Patients are younger — median age 40–50 years — and the male predominance of Type 1 is absent or reversed. Most strikingly, Type 2 AIP has a strong association with inflammatory bowel disease (IBD): approximately 25–35% of Type 2 patients have Crohn's disease or ulcerative colitis, a rate far exceeding what is seen in Type 1. Type 2 AIP responds well to steroids and, critically, has a very low relapse rate — most patients achieve durable remission after a single course of prednisolone. Long-term maintenance immunosuppression is rarely required.

The two types in numbers: In an international study of 1,064 patients from 23 centres in 10 countries (Hart and colleagues, 2013), steroids brought clinical remission in 99% of Type 1 and 92% of Type 2 patients. Relapse occurred in 31% of Type 1 versus 9% of Type 2, and in 56% of those with IgG4-related sclerosing cholangitis (bile-duct involvement). In a Mayo Clinic series of 43 people with Type 2 AIP (2016), 58% first came to medical attention with acute pancreatitis (28% with repeated attacks) and 35% with a pancreatic mass or jaundice; 10.6% had relapsed by 3 years.

Why this distinction matters in practice: A young patient with jaundice, new-onset diabetes, and a pancreatic mass who also has active ulcerative colitis is the picture in which specialists consider Type 2 AIP ahead of pancreatic cancer. An older man with jaundice, elevated serum IgG4, dry eyes, and enlarged submandibular glands is the picture that points specialists toward Type 1 AIP and IgG4-RD. Getting the subtype right guides the expected relapse risk and long-term management strategy.

Back to Table of Contents

IgG4-Related Disease — The Systemic Connection

IgG4-related disease (IgG4-RD) is the systemic condition of which Type 1 AIP is one manifestation. Recognizing IgG4-RD transformed understanding of AIP — explaining why the "autoimmune pancreatitis" patient often has problems far beyond the pancreas.

What is IgG4-RD? IgG4-RD is a fibro-inflammatory condition characterized by tumefactive (mass-forming) lesions at affected sites, dense lymphoplasmacytic infiltration with abundant IgG4-positive plasma cells, storiform fibrosis, and — in many cases — elevated serum IgG4. It can affect virtually any organ and was recognized as a unified disease entity only in the early 2000s, after Japanese researchers noticed that the same histological pattern kept appearing in patients diagnosed with seemingly unrelated conditions: Riedel's thyroiditis, Küttner's tumor (submandibular gland sclerosis), Mikulicz disease (bilateral lacrimal and salivary gland enlargement), retroperitoneal fibrosis, and interstitial nephritis. All turned out to be the same disease wearing different disguises.

Organs affected in IgG4-RD (relevant to Type 1 AIP):

Serum IgG4 interpretation: IgG4 is the least abundant of the four immunoglobulin G (IgG) subclasses (IgG1/2/3/4) in normal individuals. Normal serum IgG4 is typically below about 135–140 mg/dL (the upper limit of normal, ULN, varies by laboratory). In IgG4-RD, levels may be modestly elevated (1–2× ULN) or markedly elevated (>10× ULN). The critical thresholds are: >1× ULN = suspicious; >2× ULN = more specific for IgG4-RD when combined with appropriate clinical and radiological findings. In a study of 380 people tested at one US centre (Carruthers and colleagues, 2015), a raised IgG4 caught 90% of those with IgG4-RD but was also raised in many people without it (specificity 60%; only 34% of raised results belonged to someone with the disease). Doubling the cutoff raised specificity to 91% but missed 65% of cases (sensitivity 35%). Important caveat: approximately 5–10% of patients with undoubted IgG4-RD (confirmed histologically) have normal serum IgG4 — a negative serum IgG4 does not exclude the diagnosis. Conversely, IgG4 can be mildly elevated in pancreatic cancer, primary sclerosing cholangitis, eosinophilic granulomatosis, and other conditions — a positive serum IgG4 alone is insufficient to diagnose IgG4-RD.

Pathogenesis of IgG4-RD: Still incompletely understood. Current evidence points to an aberrant T helper 2 (Th2) and T regulatory (Treg) immune response, with overproduction of the signalling proteins interleukin-4, -5, -10 and -13 (IL-4, IL-5, IL-10, IL-13), and excessive transforming growth factor beta (TGF-beta) driving the characteristic fibrosis. IgG4 itself may not be the pathogenic effector — it is more likely a bystander marker of B cell activity. Plasmablasts (CD19+CD38+CD20-) are the best serum marker for disease activity and rituximab (anti-CD20) efficacy, driving its use in relapsing Type 1 AIP.

Back to Table of Contents

Clinical Presentation — Mimicking Pancreatic Cancer

The clinical presentation of AIP is best understood through the framework of what it most dangerously resembles — and what it does not look like.

What AIP looks like:

What AIP does NOT look like:

The cancer mimic problem in practice: Studies have documented that 2–5% of patients undergoing Whipple resection (pancreaticoduodenectomy) for presumed pancreatic cancer are found to have AIP on pathological review of the resected specimen. This represents an enormous harm — major surgery with significant morbidity and mortality for a disease that would have resolved with prednisone. The practical upshot: in any patient with a pancreatic head mass and biliary obstruction, particularly when classic cancer features (vascular involvement, metastases, a very high level of the tumour marker carbohydrate antigen 19-9, CA19-9) are absent, specialists consider AIP, and a steroid trial is sometimes used both to test the diagnosis and to treat it.

Back to Table of Contents

Imaging Features — Sausage Pancreas and Duct Changes

Imaging plays a central role in AIP diagnosis — not to confirm AIP definitively (tissue biopsy does that), but to identify features that support AIP over pancreatic cancer and allow a safer diagnostic path.

Computed tomography and magnetic resonance imaging (MRI) of the pancreas:

MRCP and ERCP — pancreatic duct findings: The pancreatic duct itself shows characteristic changes on MRCP (magnetic resonance cholangiopancreatography) or ERCP (endoscopic retrograde cholangiopancreatography):

Fluorodeoxyglucose (18F-FDG) positron emission tomography (PET)/computed tomography: AIP typically shows marked FDG (sugar-tracer) avidity in the pancreas (and in other IgG4-RD-affected organs). This can be misleading as pancreatic cancer is also FDG-avid. However, positron emission tomography/computed tomography can identify extrapancreatic IgG4-RD manifestations (salivary gland, kidney, retroperitoneal involvement) that would support AIP diagnosis.

Back to Table of Contents

Diagnosis — HISORt Criteria

The HISORt criteria, developed at the Mayo Clinic and published in 2006, provide a structured framework for diagnosing AIP when the constellation of clinical, radiological, serological, and histological findings is evaluated together. HISORt stands for Histology, Imaging, Serology, Other organ involvement, and Response to steroids.

H — Histology: Core needle biopsy of the pancreas (endoscopic ultrasound, EUS-guided fine-needle biopsy is the usual method) can show the characteristic histological features of LPSP (Type 1) or IDCP (Type 2). Histology is the most definitive diagnostic criterion but is not always safely obtainable. Whipple resection specimens provide the most tissue but represent overtreatment if done for AIP diagnosis alone.

I — Imaging: computed tomography/magnetic resonance imaging showing the "sausage-shaped" pancreas with peri-pancreatic rim, OR ERCP/MRCP showing the long irregular pancreatic duct stricture as described above. The criterion counts only imaging findings consistent with AIP, not merely non-specific ones.

S — Serology: Elevated serum IgG4 (above the laboratory's ULN, often 135–140 mg/dL; above twice the ULN, about 280 mg/dL, is more specific but misses more cases). Normal serum IgG4 does not exclude AIP, particularly Type 2. Anti-lactoferrin antibodies and anti-carbonic anhydrase II antibodies were described in early AIP literature but are not routinely used clinically. For Type 2 AIP, no specific serum marker exists.

O — Other organ involvement: Extrapancreatic IgG4-RD manifestations (sclerosing cholangitis, salivary gland enlargement, renal lesions, retroperitoneal fibrosis) strongly support Type 1 AIP. IBD (Crohn's disease or ulcerative colitis) supports Type 2 AIP. Evidence of other organ involvement can be detected clinically, serologically, or on imaging.

Rt — Response to steroids: The classic diagnostic maneuver when other criteria are insufficient to exclude pancreatic cancer confidently. A trial of prednisolone (0.5–0.6 mg/kg/day, approximately 40 mg/day for 2 weeks) with repeat imaging is offered when AIP is the leading diagnosis but tissue is unavailable. Rapid, dramatic radiological improvement — near-resolution of the pancreatic mass and normalization of the biliary stricture within 2 weeks — essentially confirms AIP. Absence of response or clinical deterioration raises serious concern for malignancy and is treated as a reason for urgent tissue diagnosis.

2011 International Consensus Diagnostic Criteria (ICDC): The most widely used international system, developed by a consortium including Japanese, Korean, European, and North American gastroenterologists. The ICDC assigns criteria in five categories (P = parenchymal imaging, D = ductal imaging, S = serology, OOI = other organ involvement, H = histology) as Level 1 (highly specific) or Level 2 (less specific) findings for each AIP subtype. Diagnosis of Type 1 or Type 2 AIP requires specific combinations of these criteria, with or without response to steroid therapy as a supplementary criterion. The ICDC provides the most nuanced framework for distinguishing Type 1 from Type 2 AIP.

When to biopsy vs. trial steroids: The decision requires clinical judgment. If malignancy cannot be excluded with reasonable confidence based on HISORt/ICDC criteria, specialists obtain tissue biopsy before steroids — because steroids can cause temporary radiological improvement even in lymphoma, which is another important differential diagnosis for a pancreatic mass with elevated IgG4. EUS-guided fine-needle biopsy (FNB) using a core biopsy needle has become the preferred method for obtaining adequate tissue for histological diagnosis without surgical risk.

Back to Table of Contents

Treatment — Steroids and Relapse Prevention

The treatment of AIP is one of the most satisfying in gastroenterology — a patient presenting with what looks like incurable pancreatic cancer achieves near-complete resolution within weeks on oral prednisone. Understanding the treatment arc — induction, taper, monitoring for relapse, and rescue therapy — is essential for long-term management.

Initial steroid therapy (induction): The standard regimen is prednisolone 0.5–0.6 mg/kg/day (approximately 30–40 mg/day) for 4 weeks, followed by a gradual taper. The most widely used taper protocol reduces the dose by 5 mg every 1–2 weeks, with a total treatment duration of approximately 3–6 months before attempting complete cessation. In patients with obstructive jaundice requiring biliary drainage (endoscopic biliary stenting), steroids are initiated after biliary decompression — though some guidelines support concurrent treatment if the clinical diagnosis of AIP is confident.

Response monitoring: Repeat imaging (computed tomography or magnetic resonance imaging) at 2 weeks of treatment is the standard practice when steroids are used diagnostically. Clinical response — reduction in jaundice, improved diabetes, weight gain — is also assessed. Serum IgG4 levels fall with treatment in Type 1 AIP (useful for monitoring) but do not normalize completely in all patients and are not used on their own to decide when to stop steroids.

Relapse:

Maintenance immunosuppression for relapsing Type 1 AIP: Options include low-dose prednisolone maintenance (2.5–7.5 mg/day for 1–3 years), azathioprine (2 mg/kg/day), or mycophenolate mofetil. Japanese guidelines traditionally favored long-term low-dose steroid maintenance; Western practice has moved toward steroid-sparing agents or rituximab for relapse-prone patients.

Rituximab (anti-CD20 B-cell depletion): The most important advance in AIP management for steroid-dependent or frequently relapsing Type 1 patients. Rituximab is given as 1000 mg intravenous (IV) × 2 doses, 2 weeks apart, or 375 mg/m² × 4 weekly doses. In a Mayo Clinic series, 10 of 12 Type 1 patients (83%) who could not take or did not respond to steroids or other immune-suppressing drugs went into complete remission on rituximab. In a 30-patient trial in IgG4-related disease (two 1000 mg doses), 97% responded, 47% were in complete remission at 6 months and 40% at 12 months. Serum IgG4 levels fall dramatically after rituximab. Retreatment at first signs of serological or clinical relapse (rising IgG4, re-emergence of symptoms) is highly effective. Rituximab has essentially replaced the need for long-term daily steroid maintenance in most relapsing patients at experienced centers.

Inebilizumab (anti-CD19 B-cell depletion): In the MITIGATE trial (2025), 135 adults with active IgG4-related disease received inebilizumab, an antibody against CD19 (a marker on B cells), or a placebo for 52 weeks, with the same steroid taper in both groups. Flares occurred in 10% on inebilizumab versus 60% on placebo (hazard ratio 0.13). Serious adverse events occurred in 18% versus 9%. The US drug label now lists IgG4-related disease in adults as an approved use of inebilizumab. The trial covered IgG4-related disease as a whole, not autoimmune pancreatitis alone.

Exocrine and endocrine management: Pancreatic enzyme replacement therapy (PERT — lipase, amylase, protease) for exocrine insufficiency. Diabetes management; insulin may be required acutely. Post-treatment recovery of endocrine function is variable — roughly 50% of AIP-related diabetes partially or completely resolves with steroid treatment; the remainder requires ongoing antidiabetic therapy. If diabetes persists 12 months after achieving AIP remission, recovery is unlikely.

Biliary interventions: Temporary biliary stenting (endoscopic or percutaneous) for severe obstructive jaundice at presentation, bridging to steroid response. Long-term biliary stenting is rarely required if AIP responds to steroids. In IgG4-SC with dominant bile duct strictures that do not respond to steroids (rare), biliary reconstruction may be necessary.

Back to Table of Contents

Complications and Long-Term Course

AIP is often portrayed as a benign, steroid-responsive condition — and in many patients it is. But the long-term course can involve significant complications, and the disease carries real morbidity if not properly managed.

Pancreatic exocrine insufficiency (PEI): Even after successful AIP treatment and resolution of pancreatic inflammation, fibrosis from the inflammatory process can leave residual exocrine insufficiency. Studies report PEI in approximately 50–80% of AIP patients at long-term follow-up, often requiring ongoing PERT. Regular monitoring of nutritional status and fat-soluble vitamin levels is part of standard follow-up.

Diabetes mellitus: AIP-associated diabetes may persist indefinitely if extensive beta-cell destruction occurred during the inflammatory episode. Pancreatic exocrine disease-related diabetes (Type 3c diabetes) has distinct pathophysiology from Type 1 or Type 2 diabetes — it involves insulin deficiency (from beta-cell destruction), and the damaged pancreas also makes less glucagon, the hormone that raises blood sugar, so low blood sugar (hypoglycemia) is a particular risk with insulin therapy. These features shape management.

Pancreatic atrophy and duct irregularity: Chronic fibroinflammatory changes can leave the pancreas atrophic and the pancreatic duct irregularly narrowed on imaging, even in well-treated patients. These changes are sequelae of prior inflammation rather than active disease and do not by themselves mean treatment has failed.

Pancreatic cancer risk: A particularly important and controversial area. Some studies suggest a modestly increased risk of pancreatic malignancy in AIP patients compared to the general population, though the absolute risk remains low. Whether this represents causal association, surveillance bias (AIP patients undergo more imaging), shared risk factors, or misclassification of early cancer as AIP in some cases is debated. Current evidence does not support intensive pancreatic cancer surveillance programs specifically for AIP, but specialists describe staying alert, particularly in patients with recurrent episodes or atypical features.

IgG4-RD progression (Type 1): Untreated or inadequately treated Type 1 AIP can be complicated by progressive IgG4-RD affecting other organs — particularly biliary (IgG4-SC leading to secondary biliary cirrhosis), renal (tubulointerstitial nephritis leading to chronic kidney disease), and retroperitoneal (retroperitoneal fibrosis causing ureteral obstruction). Regular surveillance for extrapancreatic IgG4-RD involvement is a part of Type 1 AIP long-term management.

Quality of life: Findings differ between studies. In a Dutch study of 107 patients followed for a median of about 6 years (Buijs and colleagues, 2015), quality of life and survival were not impaired compared with a reference population, although relapses (52%), exocrine insufficiency (82%) and endocrine insufficiency (57%) were common. Fatigue, ongoing diabetes management, dietary adaptations for exocrine insufficiency, and anxiety about cancer risk and disease recurrence are the burdens described. Patient education and access to multidisciplinary support significantly improve outcomes.

Back to Table of Contents

Key Research Papers

  1. Chari ST, et al. Diagnosis of autoimmune pancreatitis: the Mayo Clinic experience. Clin Gastroenterol Hepatol. 2006;4(8):1010–6. — doi:10.1016/j.cgh.2006.05.017 · PubMed PMID: 16843735
  2. Shimosegawa T, et al. International consensus diagnostic criteria for autoimmune pancreatitis: guidelines of the International Association of Pancreatology. Pancreas. 2011;40(3):352–8. — doi:10.1097/MPA.0b013e3182142fd2 · PubMed PMID: 21412117
  3. Sah RP, Chari ST. Autoimmune pancreatitis: an update on classification, diagnosis, natural history and management. Curr Gastroenterol Rep. 2012;14(2):95–105. — doi:10.1007/s11894-012-0246-8 · PubMed PMID: 22350841
  4. Kamisawa T, et al. Standard steroid treatment for autoimmune pancreatitis. Gut. 2009;58(11):1504–7. — doi:10.1136/gut.2008.172908 · PubMed PMID: 19398440
  5. Hart PA, et al. Long-term outcomes of autoimmune pancreatitis: a multicentre, international analysis. Gut. 2013;62(12):1771–6. — doi:10.1136/gutjnl-2012-303617 · PubMed PMID: 23232048
  6. Hart PA, Levy MJ, Smyrk TC, et al. Clinical profiles and outcomes in idiopathic duct-centric chronic pancreatitis (type 2 autoimmune pancreatitis): the Mayo Clinic experience. Gut. 2016;65(10):1702–9. — doi:10.1136/gutjnl-2015-309275 · PubMed PMID: 26085439
  7. Hart PA, Topazian MD, Witzig TE, et al. Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the Mayo Clinic experience. Gut. 2013;62(11):1607–15. — doi:10.1136/gutjnl-2012-302886 · PubMed PMID: 22936672
  8. Kamisawa T, Zen Y, Pillai S, Stone JH. IgG4-related disease. Lancet. 2015;385(9976):1460–71. — doi:10.1016/S0140-6736(14)60720-0 · PubMed PMID: 25481618
  9. Carruthers MN, Khosroshahi A, Augustin T, Deshpande V, Stone JH. The diagnostic utility of serum IgG4 concentrations in IgG4-related disease. Ann Rheum Dis. 2015;74(1):14–8. — doi:10.1136/annrheumdis-2013-204907 · PubMed PMID: 24651618
  10. Buijs J, Cahen DL, van Heerde MJ, et al. The long-term impact of autoimmune pancreatitis on pancreatic function, quality of life, and life expectancy. Pancreas. 2015;44(7):1065–71. — doi:10.1097/MPA.0000000000000451 · PubMed PMID: 26355549
  11. Majumder S, Chari ST. Chronic pancreatitis. Lancet. 2016;387(10031):1957–66. — doi:10.1016/S0140-6736(16)00097-0 · PubMed PMID: 26948434
  12. Carruthers MN, et al. Rituximab for IgG4-related disease: a prospective, open-label trial. Ann Rheum Dis. 2015;74(6):1171–7. — doi:10.1136/annrheumdis-2014-206605 · PubMed PMID: 25667206
  13. Stone JH, Khosroshahi A, Zhang W, et al. Inebilizumab for treatment of IgG4-related disease. N Engl J Med. 2025;392(12):1168–77. — doi:10.1056/NEJMoa2409712 · PubMed PMID: 39541094
  14. Masamune A, Sano T, Takikawa T, et al. Nationwide epidemiological survey of autoimmune pancreatitis in Japan in 2021. J Gastroenterol. 2026;61(10):1502–11. — doi:10.1007/s00535-026-02438-w · PubMed PMID: 42154026
  15. Kawa S, Kamisawa T, Notohara K, et al. Japanese Clinical Diagnostic Criteria for Autoimmune Pancreatitis, 2018: revision of Japanese Clinical Diagnostic Criteria for Autoimmune Pancreatitis, 2011. Pancreas. 2020;49(1):e13–e14. — doi:10.1097/MPA.0000000000001443 · PubMed PMID: 31856100

PubMed topic searches:

  1. PubMed: Autoimmune pancreatitis diagnosis treatment
  2. PubMed: IgG4-related disease pancreas sclerosing cholangitis
  3. PubMed: Autoimmune pancreatitis type 1 type 2 LPSP IDCP
  4. PubMed: Autoimmune pancreatitis steroid treatment relapse
  5. PubMed: Rituximab IgG4 related disease autoimmune pancreatitis

Back to Table of Contents

Connections

  1. Gastroenterology
  2. Pancreatitis (acute and chronic)
  3. IgG4-Related Disease (the systemic condition behind Type 1 AIP)
  4. Primary Sclerosing Cholangitis (biliary differential)
  5. Primary Biliary Cholangitis (biliary autoimmune)
  6. Inflammatory Bowel Disease (Type 2 AIP association)
  7. Diabetes (AIP-related Type 3c diabetes)
  8. Pancreatic Cancer (critical differential diagnosis)
  9. Gallbladder Disease
  10. Colorectal Cancer
  11. Liver Disease

Back to Table of Contents